Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data — But BTIG Says Therapy’s Benefit Is Hard To Measure

Arcturus Therapeutics (ARCT) was in focus Thursday after promising Phase 2 data for its experimental treatment for a rare liver disease drew broadly positive takes from analysts.ARCT shares were up nearly 7% at the time of writing, bucking the broader biotech weakness. The State Street SPDR S&P Bio…